Myriad Genetics Expands MyRisk Hereditary Cancer Test with 15 New Clinically Actionable Genes
Myriad Genetics Inc. has expanded its MyRisk® Hereditary Cancer Test to include 15 new clinically actionable genes, bringing the total to 63 genes recommended by national oncology guidelines. This enhancement aims to provide comprehensive genetic information for cancer treatment decisions, surveillance planning, and family risk assessment. The announcement did not clarify if these results have been presented at a scientific meeting.
Myriad Genetics Inc. has announced the expansion of its MyRisk® Hereditary Cancer Test to include 15 additional clinically actionable genes. This update means the test now covers 63 genes that are strongly recommended by national oncology guidelines, such as those from the NCCN and ASCO. The expanded panel is designed to support evolving clinical needs by providing more comprehensive genetic information to guide cancer treatment decisions, surveillance planning, and family risk assessment. The announcement did not specify if these results have already been presented at a scientific meeting or if they will be presented in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
